US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Evommune

12.66

-0.5700-4.31%

Pre-market: 12.45-0.2100-1.66%08:36 EDT

Volume:571.94K

Turnover:7.27M

Market Cap:459.46M

PE:-4.85

High:13.13

Open:13.08

Low:12.61

Close:13.23

52wk High:33.20

52wk Low:10.47

Shares:36.29M

Float Shares:19.98M

Volume Ratio:1.89

T/O Rate:2.86%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6090

EPS(LYR):-11.2228

ROE:-52.11%

ROA:-31.99%

PB:1.66

PE(LYR):-1.13

Loading ...

Overview Company News Filings

Evommune - to Report Evo756 Phase 2B Atopic Dermatitis Data in Q3 2026

THOMSON REUTERS

Evommune Announces Top-line Results from Evo756 Phase 2B Trial in Moderate-to-severe Chronic Spontaneous Urticaria

THOMSON REUTERS

Evommune - Initiates Screening for Evo756 Phase 2B Migraine Trial

THOMSON REUTERS

Evommune - to Continue Evo756 Development in Atopic Dermatitis and Migraine

THOMSON REUTERS

Evommune - Evo756 Phase 2B Csu Trial Did not Meet Primary Endpoint at 12 Weeks

THOMSON REUTERS

Evommune CEO Luis C. Pena Sells 7,438 Common Shares Worth $168,904.98

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (ALC)

Evommune publishes presentation on interstitial fluid proteomics in chronic urticaria patients

Evommune director David E. Cohen disposes of common shares worth $123,166.76

Evommune Chief Scientific Officer Jeegar Pravinkumar Patel disposes of common shares worth $379,631.38

Evommune President and CEO Luis C. Pena sells 16,787 shares worth $381,694.38

Evommune Stockholders Reelect Directors and Ratify Auditor

Evommune shareholders ratify BDO as independent auditor for fiscal 2026

Evommune Chief Business & Legal Officer Gregory S. Moss disposes of 14,223 common shares worth $324,855.09

Evommune CFO Kyle Carver disposes of 18,175 common shares worth $415,117.00

Evommune Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Matt Phipps Reiterates Buy on Evommune as EVO301 Data Strengthen IL‑18 Blockade Thesis and Support Blockbuster Potential

Evommune Is Maintained at Overweight by Morgan Stanley

Evommune price target raised to $55 from $54 at Morgan Stanley

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/EVMN/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EVMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":12.66,"timestamp":1788206400000,"preClose":13.23,"halted":0,"volume":571940,"hourTrading":{"tag":"盘前","latestPrice":12.45,"preClose":12.66,"latestTime":"08:36 EDT","volume":162,"amount":2056.210353,"timestamp":1788266201339,"change":-0.21,"changeRate":-0.016588,"amplitude":0.019747},"delay":0,"changeRate":-0.04308390022675739,"floatShares":19982000,"shares":36292113,"eps":-2.609,"marketStatus":"Pre-Mkt","change":-0.57,"latestTime":"09-01 08:40:08 EDT","open":13.08,"high":13.13,"low":12.61,"amount":7274548.89938,"amplitude":0.039305,"askPrice":13,"askSize":100,"bidPrice":12.01,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-2.609,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788269400000},"marketStatusCode":1,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":12.66,"preHourTrading":{"tag":"盘前","latestPrice":12.45,"preClose":12.66,"latestTime":"08:36 EDT","volume":162,"amount":2056.210353,"timestamp":1788266201339,"change":-0.21,"changeRate":-0.016588,"amplitude":0.019747},"postHourTrading":{"tag":"盘后","latestPrice":12.66,"preClose":12.66,"latestTime":"19:36 EDT","volume":44185,"amount":559381.883,"timestamp":1788219387436,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.88761477408625,"impliedVol":1.2663,"impliedVolPercentile":0.5556},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","floatShares":19982000,"roa":"-31.99%","roe":"-52.11%","lyrEps":-11.222761,"volumeRatio":1.88761477408625,"shares":36292113,"dividePrice":0,"high":13.13,"amplitude":0.039305,"preClose":13.23,"low":12.61,"week52Low":10.47,"pbRate":"1.66","psRate":"45.95","week52High":33.2,"institutionHeld":0,"latestPrice":12.66,"committee":0.666667,"eps":-2.609,"divideRate":0,"volume":571940,"delay":0,"ttmEps":-2.609,"open":13.08,"prevYearClose":17.12,"prevWeekClose":13.23,"prevMonthClose":12.66,"prevQuarterClose":13.29,"fiveDayClose":13.67,"twentyDayClose":11.59,"sixtyDayClose":20.69},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVMN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"EVMN","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2026-05-07","symbol":"EVMN","fiscalQuarterEnding":"2026/03","expectedEps":-0.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2026-03-05","symbol":"EVMN","fiscalQuarterEnding":"2025/12","expectedEps":-0.82,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-1.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVMN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5833,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1787976000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVMN","date":"2026-08-31","current":-4.852434,"percent":1,"low":-16.229076,"twenty":-12.40534,"median":-9.712404,"eighty":-6.403835,"high":-5.071879,"avg":-9.852269,"sd":2.850991,"marketCap":480144654},"quantilePoints":[{"date":"2025-11-07","current":-9.395174,"twenty":-7.823584,"median":-7.430686,"eighty":-7.430686,"marketCap":608469038},{"date":"2025-11-14","current":-8.461694,"twenty":-9.04686,"median":-8.505813,"eighty":-7.430686,"marketCap":548013143},{"date":"2025-11-21","current":-8.689259,"twenty":-9.04686,"median":-8.689259,"eighty":-7.430686,"marketCap":562751147},{"date":"2025-11-28","current":-9.618094,"twenty":-9.051504,"median":-8.707835,"eighty":-8.049291,"marketCap":622906267},{"date":"2025-12-05","current":-10.184684,"twenty":-9.618094,"median":-8.986487,"eighty":-8.483986,"marketCap":659600890},{"date":"2025-12-12","current":-9.657505,"twenty":-9.633858,"median":-9.000419,"eighty":-8.483986,"marketCap":592227156},{"date":"2025-12-19","current":-7.716136,"twenty":-9.618094,"median":-8.986487,"eighty":-8.244704,"marketCap":473176635},{"date":"2025-12-26","current":-9.042428,"twenty":-9.528926,"median":-9.016673,"eighty":-8.355807,"marketCap":554508795},{"date":"2026-01-02","current":-8.800817,"twenty":-9.392482,"median":-9.003431,"eighty":-8.469125,"marketCap":539692472},{"date":"2026-01-09","current":-9.37143,"twenty":-9.380689,"median":-8.972554,"eighty":-8.293747,"marketCap":574684215},{"date":"2026-01-16","current":-10.075701,"twenty":-9.649623,"median":-9.019686,"eighty":-8.354639,"marketCap":617872222},{"date":"2026-01-23","current":-9.710714,"twenty":-9.690151,"median":-9.037572,"eighty":-8.461694,"marketCap":595490116},{"date":"2026-01-30","current":-11.129537,"twenty":-9.775997,"median":-9.042428,"eighty":-8.498847,"marketCap":682496613},{"date":"2026-02-06","current":-8.564346,"twenty":-9.775997,"median":-9.064213,"eighty":-8.549933,"marketCap":525191389},{"date":"2026-02-13","current":-14.332171,"twenty":-9.885497,"median":-9.065437,"eighty":-8.563866,"marketCap":878891712},{"date":"2026-02-20","current":-14.769127,"twenty":-10.094711,"median":-9.253195,"eighty":-8.56425,"marketCap":905687191},{"date":"2026-02-27","current":-13.689588,"twenty":-10.579486,"median":-9.338016,"eighty":-8.621921,"marketCap":839486596},{"date":"2026-03-06","current":-11.484529,"twenty":-11.200535,"median":-9.381712,"eighty":-8.67867,"marketCap":790939493},{"date":"2026-03-13","current":-12.018327,"twenty":-12.245567,"median":-9.479385,"eighty":-8.689259,"marketCap":827702188},{"date":"2026-03-20","current":-12.321662,"twenty":-12.396972,"median":-9.618094,"eighty":-8.70412,"marketCap":848592844},{"date":"2026-03-27","current":-12.379191,"twenty":-12.362455,"median":-9.695292,"eighty":-8.728757,"marketCap":852554865},{"date":"2026-04-02","current":-11.725452,"twenty":-12.336306,"median":-9.710846,"eighty":-8.771001,"marketCap":807531900},{"date":"2026-04-10","current":-14.983685,"twenty":-12.570606,"median":-9.775997,"eighty":-8.798761,"marketCap":1031926357},{"date":"2026-04-17","current":-14.000462,"twenty":-13.015147,"median":-9.975459,"eighty":-8.828576,"marketCap":964211818},{"date":"2026-04-24","current":-13.514081,"twenty":-13.425068,"median":-10.075701,"eighty":-8.877926,"marketCap":930714732},{"date":"2026-05-01","current":-12.44718,"twenty":-13.370677,"median":-10.26642,"eighty":-8.898489,"marketCap":857237253},{"date":"2026-05-08","current":-11.767292,"twenty":-13.351187,"median":-10.76455,"eighty":-8.934568,"marketCap":810413370},{"date":"2026-05-15","current":-10.76944,"twenty":-13.300701,"median":-10.81684,"eighty":-8.966981,"marketCap":818337411},{"date":"2026-05-22","current":-11.162865,"twenty":-13.208546,"median":-10.76944,"eighty":-8.989273,"marketCap":848232660},{"date":"2026-05-29","current":-11.058584,"twenty":-13.135327,"median":-10.864241,"eighty":-9.002829,"marketCap":840308618},{"date":"2026-06-05","current":-9.807205,"twenty":-13.084182,"median":-10.80499,"eighty":-9.017037,"marketCap":745220116},{"date":"2026-06-12","current":-9.807205,"twenty":-13.030837,"median":-10.755219,"eighty":-9.036643,"marketCap":745220116},{"date":"2026-06-18","current":-9.788245,"twenty":-12.946112,"median":-10.53322,"eighty":-9.042258,"marketCap":743779381},{"date":"2026-06-26","current":-11.43779,"twenty":-12.867664,"median":-10.624868,"eighty":-9.042428,"marketCap":869123316},{"date":"2026-07-02","current":-6.07677,"twenty":-12.855112,"median":-10.547048,"eighty":-9.032928,"marketCap":461755529},{"date":"2026-07-10","current":-6.403835,"twenty":-12.813273,"median":-10.376014,"eighty":-8.958621,"marketCap":486608205},{"date":"2026-07-17","current":-5.550622,"twenty":-12.635456,"median":-10.177718,"eighty":-8.800817,"marketCap":421775136},{"date":"2026-07-24","current":-5.36576,"twenty":-12.598847,"median":-10.075701,"eighty":-8.689259,"marketCap":407727971},{"date":"2026-07-31","current":-5.37998,"twenty":-12.561192,"median":-10.06542,"eighty":-8.56425,"marketCap":408808522},{"date":"2026-08-07","current":-5.090694,"twenty":-12.489019,"median":-9.881902,"eighty":-8.43493,"marketCap":481925817},{"date":"2026-08-14","current":-5.393903,"twenty":-12.464961,"median":-9.807205,"eighty":-8.177768,"marketCap":510630029},{"date":"2026-08-21","current":-5.202222,"twenty":-12.450318,"median":-9.782121,"eighty":-7.430686,"marketCap":492483973},{"date":"2026-08-28","current":-5.16772,"twenty":-12.413708,"median":-9.712404,"eighty":-6.987812,"marketCap":489217683},{"date":"2026-08-31","current":-5.071879,"twenty":-12.40534,"median":-9.712404,"eighty":-6.403835,"marketCap":480144654}],"updateTime":1788266408337},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVMN\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2647937110","title":"Evommune - to Report Evo756 Phase 2B Atopic Dermatitis Data in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647937110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647937110?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371940","title":"Evommune Announces Top-line Results from Evo756 Phase 2B Trial in Moderate-to-severe Chronic Spontaneous Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371940?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371174","title":"Evommune - Initiates Screening for Evo756 Phase 2B Migraine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371174?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371173","title":"Evommune - to Continue Evo756 Development in Atopic Dermatitis and Migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371173?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647160371","title":"Evommune - Evo756 Phase 2B Csu Trial Did not Meet Primary Endpoint at 12 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2647160371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647160371?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646842938","title":"Evommune CEO Luis C. Pena Sells 7,438 Common Shares Worth $168,904.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2646842938","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646842938?lang=en_us&edition=fundamental","pubTime":"2026-06-25 08:00","pubTimestamp":1782345623,"startTime":"0","endTime":"0","summary":"Evommune CEO Luis C. Pena sells 7,438 common shares worth $168,904.98Evommune President, CEO, director Luis C. Pena sold 7,438 common shares on June 22, 2026.Sale priced at a weighted average of USD 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL1C0T6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Evommune CEO Luis C. Pena Sells 7,438 Common Shares Worth $168,904.98","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645038980","title":"Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2645038980","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645038980?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:55","pubTimestamp":1782165309,"startTime":"0","endTime":"0","summary":"Clear Street reiterated a Buy rating and $53 price target on Evommune (EVMN), saying Abbvie’s (ABBV) proposed acquisition of Apogee (APGE) provides...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-deal-gives-positive-readthrough-to-evommune-pipeline-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-deal-gives-positive-readthrough-to-evommune-pipeline-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE","LU0256863811.USD","LU1551013425.SGD","LU0203347892.USD","LU0861579265.USD","IE0004445239.USD","BK4534","IE00BJT1NW94.SGD","LU1244550221.USD","LU2129689431.USD","LU1267930490.SGD","LU0820561818.USD","BK4139","EVMN","IE0009355771.USD","LU2089283258.USD","ABBV","LU1244550577.SGD","LU0859254822.USD","BK4581","IE000BZT7R73.USD","LU0689626769.HKD","LU2237443465.HKD","LU0203345920.USD","LU0211327993.USD","LU1585245621.USD","LU1934455194.USD","LU2347655156.SGD","LU1732800096.USD","LU1839511570.USD","SG9999011175.SGD","LU0820561909.HKD","LU0211328371.USD","LU0965509010.AUD","LU1934455277.USD","LU1989772923.USD","LU1989771016.USD","LU2357627491.SGD","IE0002141913.USD","LU0057025933.USD","LU0661504455.SGD","LU1496350171.SGD","LU0912757837.SGD","LU0472753341.HKD","LU1291159041.SGD","LU0098860793.USD","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD","LU1989772840.SGD","LU2023251221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642026057","title":"Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (ALC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642026057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642026057?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:31","pubTimestamp":1781263876,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (AL...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evommune-inc-evmn-immunome-imnm-and-alcon-alc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evommune-inc-evmn-immunome-imnm-and-alcon-alc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4534","LU2265009873.SGD","BK4585","HCSG","LU0029874061.USD","BK4563","LU1804176565.USD","IMNM","LABU","EVMN","ALC","BK4581","BK4198","XBI","BK4137","BK4588","BK4139","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642535478","title":"Evommune publishes presentation on interstitial fluid proteomics in chronic urticaria patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642535478","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642535478?lang=en_us&edition=fundamental","pubTime":"2026-06-11 01:23","pubTimestamp":1781112223,"startTime":"0","endTime":"0","summary":"Evommune published a medical research presentation on proteomic profiling of dermal interstitial fluid in chronic inducible urticaria and chronic spontaneous urticaria.Lesional samples showed higher mast cell activation markers versus non-lesional skin, supporting mast cell involvement in both conditions.The analysis found enrichment of endogenous MRGPRX2 ligands in lesions, pointing to a shared MRGPRX2-driven disease mechanism.Proteomic signatures also indicated elevated inflammatory cytokines and chemokines in lesional skin, consistent across both patient groups.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief on June 10, 2026, and is solely responsible for ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL3p2TCy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640180426","title":"Evommune director David E. Cohen disposes of common shares worth $123,166.76","url":"https://stock-news.laohu8.com/highlight/detail?id=2640180426","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640180426?lang=en_us&edition=fundamental","pubTime":"2026-06-04 08:03","pubTimestamp":1780531421,"startTime":"0","endTime":"0","summary":"Evommune director David E. Cohen sold 6,056 common shares on June 2, 2026 at weighted-average prices of USD 20.21 and USD 21.38.Holdings fell to 17,609 common shares following the sales.Cohen also received stock options for 15,673 shares at an exercise price of USD 19.82, expiring June 1, 2036.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDLbPnQqX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640429180","title":"Evommune Chief Scientific Officer Jeegar Pravinkumar Patel disposes of common shares worth $379,631.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2640429180","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640429180?lang=en_us&edition=fundamental","pubTime":"2026-06-04 08:03","pubTimestamp":1780531399,"startTime":"0","endTime":"0","summary":"Evommune Chief Scientific Officer Jeegar Pravinkumar Patel sold 16,687 common shares on June 1 at USD 22.74.He exercised employee stock options for 13,512 shares at USD 3.84 on the same day.He held 46,403 common shares following the transactions.He also held 29,330 employee stock options after the exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL5dPXlG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640718049","title":"Evommune President and CEO Luis C. Pena sells 16,787 shares worth $381,694.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2640718049","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640718049?lang=en_us&edition=fundamental","pubTime":"2026-06-04 08:02","pubTimestamp":1780531365,"startTime":"0","endTime":"0","summary":"Shares sold at a weighted average price of $22.74.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL7m24PZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Evommune President and CEO Luis C. Pena sells 16,787 shares worth $381,694.38","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640492981","title":"Evommune Stockholders Reelect Directors and Ratify Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2640492981","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640492981?lang=en_us&edition=fundamental","pubTime":"2026-06-03 05:31","pubTimestamp":1780435906,"startTime":"0","endTime":"0","summary":"Evommune, Inc. ( ($EVMN) ) has shared an announcement. On June 2, 2026, Evommune, Inc. held its 2026 Annual Meeting of Stockholders, where a quorum...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommune-stockholders-reelect-directors-and-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommune-stockholders-reelect-directors-and-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640992377","title":"Evommune shareholders ratify BDO as independent auditor for fiscal 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640992377","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640992377?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:10","pubTimestamp":1780431038,"startTime":"0","endTime":"0","summary":"Evommune held its annual shareholder meeting on June 2, 2026.Shareholders backed the selection of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.Two director nominees were elected to the board, with terms running to the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL411SHP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640989149","title":"Evommune Chief Business & Legal Officer Gregory S. Moss disposes of 14,223 common shares worth $324,855.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989149","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640989149?lang=en_us&edition=fundamental","pubTime":"2026-06-02 08:00","pubTimestamp":1780358445,"startTime":"0","endTime":"0","summary":"Evommune Chief Business & Legal Officer Gregory S. Moss sold 14,223 common shares on May 28, 2026 for USD 22.83 each.He acquired 14,223 common shares at USD 1.71 through an employee stock option exercise on the same day.Directly held common shares fell to 60,835 following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL1rMNcT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640915998","title":"Evommune CFO Kyle Carver disposes of 18,175 common shares worth $415,117.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2640915998","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640915998?lang=en_us&edition=fundamental","pubTime":"2026-06-02 08:00","pubTimestamp":1780358408,"startTime":"0","endTime":"0","summary":"Evommune CFO Kyle Carver cut his stake to 59,335 shares in transactions dated May 28, 2026.Sold 18,175 shares at a weighted average price of $22.84.Acquired 15,000 shares at $2.99 through an employee stock option exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL9RFvLz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Evommune CFO Kyle Carver disposes of 18,175 common shares worth $415,117.00","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638164695","title":"Evommune Price Target Maintained With a $50.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2638164695","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638164695?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:03","pubTimestamp":1779793380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 26, 2026 07:03 ET (11:03 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635079217","title":"Matt Phipps Reiterates Buy on Evommune as EVO301 Data Strengthen IL‑18 Blockade Thesis and Support Blockbuster Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2635079217","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635079217?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:15","pubTimestamp":1778836538,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has maintained their bullish stance on EVMN stock, giving a Buy rating on May 12. Matt Phipps has given his Buy r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/matt-phipps-reiterates-buy-on-evommune-as-evo301-data-strengthen-il‑18-blockade-thesis-and-support-blockbuster-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/matt-phipps-reiterates-buy-on-evommune-as-evo301-data-strengthen-il‑18-blockade-thesis-and-support-blockbuster-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634323983","title":"Evommune Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2634323983","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634323983?lang=en_us&edition=fundamental","pubTime":"2026-05-12 01:21","pubTimestamp":1778520060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 13:21 ET (17:21 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634355812","title":"Evommune price target raised to $55 from $54 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2634355812","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634355812?lang=en_us&edition=fundamental","pubTime":"2026-05-11 23:52","pubTimestamp":1778514775,"startTime":"0","endTime":"0","summary":"Morgan Stanley raised the firm’s price target on Evommune (EVMN) to $55 from $54 and keeps an Overweight rating on the shares. Published first on T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-price-target-raised-to-55-from-54-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-price-target-raised-to-55-from-54-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":91,"code":"91000000","status":"200"}]}}